The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“11BHSD1 overexpression in mouse adipose tissue leads to an increase of triacylglycerol and cholesterol plasma levels [80], while 11BHSD1 overexpression in liver provokes insulin resistance, hepatic steatosis, and disturbed lipid synthesis [81].”
BackgroundDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Chronic stress and comfort foods: Self-medication and abdominal obesity
Dallman, M. F., Pecoraro, N. C., & la Fleur, S. E. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2004.11.004 · Cited by 656
Cardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604 · cited 3×
“The risk seems to increase with duration of exposure and daily dosage [36, 54, 105].”
BackgroundMolecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419 · cited 1×
“The genomic mechanism of glucocorticoid action can be divided into two processes: ‘transrepression’, which is responsible for a large number of desirable anti-inflammatory and immunomodulating effects, and ‘transactivation’ which is associated with some adverse events [117].”
BackgroundPrevalence of oral glucocorticoid usage in the United States: a general population perspective
Overman, R. A., Yeh, J., & Deal, C. L. (2013) · Arthritis Care & Research · doi:10.1002/acr.21796 · Cited by 405 · cited 1×
“2 % of the general population undergoes systemic glucocorticoid therapy, most of them being treated for months or years [1, 2].”
BackgroundValassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402 · cited 1×
“Up to 90 % of patients with endogenous hypercortisolism experience weight gain and 70 % of them are considered obese [16, 28].”
BackgroundMacfarlane, D. P., Forbes, S., & Walker, B. R. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0054 · Cited by 385 · cited 1×
“kines also contribute to glucocorticoid effects on lipid metabolism [10, 79].”
BackgroundSaad, M. J., Folli, F., Kahn, J. A., & Kahn, C. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116803 · Cited by 349
Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319
Glucocorticoids and the risk for initiation of hypoglycemic therapy
Gurwitz, J. H. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420010131015 · Cited by 314
Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes.
Slavin, B. G., Ong, J. M., & Kern, P. A. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41151-4 · Cited by 261
Adipogenic and lipolytic effects of chronic glucocorticoid exposure
Campbell, J. E., Peckett, A. J., D'souza, A. M., Hawke, T. J., & Riddell, M. C. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00045.2010 · Cited by 228
Risk of Diabetes Associated With Prescribed Glucocorticoids in a Large Population
Gulliford, M. C., Charlton, J., & Latinovic, R. (2006) · Diabetes Care · doi:10.2337/dc06-1499 · Cited by 211
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2729 · Cited by 203 · cited 2×
“It seems more appropriate to measure postprandial blood glucose concentration [64, 71, 72].”
BackgroundDiabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome
Pivonello, R., De Leo, M., Vitale, P., Cozzolino, A., Simeoli, C., De Martino, M. C., Lombardi, G., & Colao, A. (2010) · Neuroendocrinology · doi:10.1159/000314319 · Cited by 190
Lundgren, M., Burén, J., Ruge, T., Myrnäs, T., & Eriksson, J. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031157 · Cited by 163
Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases
Uzu, T., Harada, T., Sakaguchi, M., Kanasaki, M., Isshiki, K., Araki, S., Sugiomoto, T., Koya, D., Haneda, M., Kashiwagi, A., et al. (2006) · Nephron Clinical Practice · doi:10.1159/000097598 · Cited by 136
Glucocorticoid-induced hypertension: from mouse to man
Whitworth, J. A., Schyvens, C. G., Zhang, Y., Mangos, G. J., & Kelly, J. J. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03584.x · Cited by 66
Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome
Fardet, L., Cabane, J., Kettaneh, A., Lebbe, C., & Flahault, A. (2007) · Rheumatology · doi:10.1093/rheumatology/kem062 · Cited by 59 · cited 3×
“People with glucocorticoid-induced lipodystrophy are more likely to develop an unfavorable lipid profile than people exposed to the same amount of glucocorticoids but who do not present with morphological changes [34].”
BackgroundSelf-citationYuen, K. C. J., McDaniel, P. A., & Riddle, M. C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04242.x · Cited by 58 · cited 2×
“It seems more appropriate to measure postprandial blood glucose concentration [64, 71, 72].”
BackgroundDescription des prescriptions de corticothérapies orales en population générale
Fardet, L., Petersen, I., & Nazareth, I. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.02.022 · Cited by 31
Self-citationFardet, L., Kettaneh, A., Gérol, J., Tolédano, C., Tiev, K.-P., & Cabane, J. (2009) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.03.009 · Cited by 14
Self-citation
Research works printed but not linked: 110
- Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–8. · DOI · Paper page
- Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 [cited 2012 Jul 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21938845 .
- Fardet L. Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy. Rev Med Interne. 2013;34(5):303–9. · DOI
- Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metab Clin Exp. 2011;60(11):1500–10. · DOI · Paper page
- Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):86–90. · DOI · Paper page
- Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275(1–2):43–61. · DOI · Paper page
- Fève B, Emorine LJ, Briend-Sutren MM, Lasnier F, Strosberg AD, Pairault J. Differential regulation of beta 1- and beta 2-adrenergic receptor protein and mRNA levels by glucocorticoids during 3T3-F442A adipose differentiation. J Biol Chem. 1990;265(27):16343–9. · DOI
- Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology. 1999;140(7):3188–96. · DOI · Paper page
- Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest. 1989;84(5):1663–70. · DOI · Paper page
- Chanson P, Salenave S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):96–101. · DOI
- Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 2008;22(6):1672–83. · DOI · Paper page
- Lee M-J, Gong D-W, Burkey BF, Fried SK. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. Am J Physiol Endocrinol Metab. 2011;300(3):E571–80. · DOI
- Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab. 1990;71(5):1215–9. · DOI · Paper page
- Lindroos J, Husa J, Mitterer G, et al. Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab. 2013;18(1):62–74. · DOI
- Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line. Mol Cell Endocrinol. 2000;165(1–2):7–15. · DOI
- Strack AM, Sebastian RJ, Schwartz MW, Dallman MF. Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol. 1995;268(1 Pt 2):R142–9.
- Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996;271(2 Pt 1):E317–25.
- Spencer SJ, Tilbrook A. The glucocorticoid contribution to obesity. Stress. 2011;14(3):233–46. · DOI
- Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids–food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology. 2004;145(6):2633–8. · DOI · Paper page
- Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6. · DOI · Paper page
- Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57(4):604–9. · DOI
- Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr. 1986;43(5):758–69. · DOI
- Schou AJ, Heuck C, Wolthers OD. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids. 2003;68(6):525–31. · DOI
- Arena C, Morin A-S, Blanchon T, et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol. 2010;163(4):832–7. · DOI
- Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ. 2012;345:e4928. · DOI
- Fardet L, Antuna-Puente B, Vatier C, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf). 2013;78(1):43–51. · DOI
- Fardet L, Kettaneh A, Tiev K-P, et al. Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. Eur J Intern Med. 2008;19(5):340–4. · DOI
- Fardet L, Flahault A, Kettaneh A, Tiev KP, Tolédano C, Cabane J. Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients. Rev Med Interne. 2007;28(12):825–31. · DOI
- Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702–11. · DOI
- Barahona M-J, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3365–71. · DOI · Paper page
- Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95(7):3309–17. · DOI
- Vander Kooi BT, Onuma H, Oeser JK, et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19(12):3001–22. · DOI
- Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19(1):29–34. · DOI
- Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development. Diabetes Metab Res Rev. 2012;28(7):560–73. · DOI
- Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem. 1997;272(6):3216–22. · DOI
- Borboni P, Porzio O, Magnaterra R, et al. Quantitative analysis of pancreatic glucokinase gene expression in cultured beta cells by competitive polymerase chain reaction. Mol Cell Endocrinol. 1996;117(2):175–81. · DOI
- Ullrich S, Berchtold S, Ranta F, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090–9. · DOI · Paper page
- Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metab Clin Exp. 1998;47(1):3–6. · DOI · Paper page
- Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717–20. · DOI · Paper page
- Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619–32. · DOI · Paper page
- Kim SY, Yoo C-G, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011;26(2):264–7. · DOI
- Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–81. · DOI · Paper page
- Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17(1):15–9. · DOI
- Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol. 1985;5(3):196–202. · DOI
- Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997;90(6):880–3. · DOI
- Feldman-Billard S, Lissak B, Kassaei R, Benrabah R, Héron E. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology. 2005;112(3):511–5. · DOI
- Reynolds RM, Labad J, Sears AV, et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol. 2012;166(5):861–8. · DOI
- Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford). 2012;51(6):1112–9. · DOI
- Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6. · DOI · Paper page
- Andrade-Sierra J, Contreras AM, Monteon FJ, et al. Risk factors and incidence of posttransplant diabetes mellitus in Mexican kidney recipients. Arch Med Res. 2006;37(8):961–6. · doi:10.1016/j.arcmed.2006.05.004
- Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979–83. · DOI · Paper page
- Bruno A, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med. 1987;147(4):679–80. · DOI
- Pagano G, Lombardi A, Ferraris GM, Imbimbo B, Cavallo Perin P. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol. 1982;22(5):469–71. · DOI
- Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant. 2014;29(3):698–705. · DOI
- Kasayama S, Tanaka T, Hashimoto K, Koga M, Kawase I. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care. 2002;25(12):2359–60. · DOI
- Van Raalte DH, van Genugten RE, Linssen MML, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34(2):412–7. · DOI
- Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6(1):23–5. · DOI · Paper page
- Onwubalili JK, Obineche EN. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant. 1992;7(4):346–9. · DOI
- Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8(3):212–23. · DOI
- Fain JN, Cheema P, Tichansky DS, Madan AK. Stimulation of human omental adipose tissue lipolysis by growth hormone plus dexamethasone. Mol Cell Endocrinol. 2008;295(1–2):101–5. · DOI
- Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101(18):7088–93. · DOI · Paper page
- Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316(2):154–64. · DOI · Paper page
- el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973;2(5858):85–6. · DOI
- Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J. 1980;56(657):491–3. · DOI
- Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53(4):528–35. · DOI
- Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metab Clin Exp. 1984;33(6):521–6. · DOI
- Brotman DJ, Girod JP, Garcia MJ, et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab. 2005;90(6):3202–8. · DOI
- Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–72. · DOI
- Kuroki Y, Kaji H, Kawano S, et al. Prospective short-term effects of glucocorticoid treatment on glucose and lipid metabolism in Japanese. Intern Med. 2010;49(10):897–902. · DOI
- Greenman Y. Management of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):91–5. · DOI
- Pinheiro CH da J, Sousa Filho WM de, Oliveira Neto J de, et al. Exercise prevents cardiometabolic alterations induced by chronic use of glucocorticoids. Arq Bras Cardiol. 2009;93(4):400–8, 392–400.
- Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab. 1991;72(5):1060–6. · DOI
- Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62(5):375–91.
- Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl. 1996;14(5):S37–41.
- Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens. 1989;7(7):537–49. · DOI
- Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na + retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest. 1995;18(7):586–91. · DOI
- Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008;19(7):1291–9. · DOI
- Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409–13. · DOI
- Peppa M, Krania M, Raptis SA. Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review. Integr Blood Press Control. 2011;4:7–16. · DOI
- Ong SLH, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am. 2011;40(2):393–407, ix. · DOI
- Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995;8(8):823–8. · DOI
- Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(1):72–5. · DOI · Paper page
- Zacharieva S, Torbova S, Orbetzova M, et al. Trandolapril in Cushing’s disease: short-term trandolapril treatment in patients with Cushing’s disease and essential hypertension. Methods Find Exp Clin Pharmacol. 1998;20(5):433–8. · DOI
- Zacharieva S, Orbetzova M, Natchev E, et al. Losartan in Cushing’s syndrome. Methods Find Exp Clin Pharmacol. 1998;20(2):163–8. · doi:10.1358/mf.1998.20.2.472459
- Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101(8):759–67. · DOI · Paper page
- Trementino L, Arnaldi G, Appolloni G, et al. Coagulopathy in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):55–9. · DOI
- Ren R, Oakley RH, Cruz-Topete D, Cidlowski JA. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology. 2012;153(11):5346–60. · DOI
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70. · DOI · Paper page
- Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65. · DOI · Paper page
- Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–20. · DOI · Paper page
- Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–83. · DOI
- Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–17. · DOI · Paper page
- Vayssière BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997;11(9):1245–55. · DOI · Paper page
- Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol. 2001;166(3):1975–82. · DOI · Paper page
- Schäcke H, Schottelius A, Döcke W-D, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 2004;101(1):227–32. · DOI · Paper page
- Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317–33. · DOI
- Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 1995;22(9):1660–2.
- Miner JN, Tyree C, Hu J, et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol. 2003;17(1):117–27. · DOI
- Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003;17(5):860–9. · DOI · Paper page
- Patel R, Williams-Dautovich J, Cummins CL. Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol Endocrinol. 2014;28(7):999–1011. · DOI
- Yi C-X, Foppen E, Abplanalp W, et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes. 2012;61(2):339–45. · DOI
- Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet. 1993;342(8877):949–54. · DOI · Paper page
- Rupa V, Jacob M, Mathews MS, Seshadri MS. A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol. 2010;267(2):233–8. · DOI
- Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51. · DOI · Paper page
- Secchi A, Pastore MR, Sergi A, Pontiroli AE, Pozza G. Prednisone administration in recent onset type I diabetes. J Autoimmun. 1990;3(5):593–600. · DOI
- Powell-Tuck J, Bown RL, Chambers TJ, Lennard-Jones JE. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263–70. · doi:10.1159/000198667
- Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest. 1965;48(3):287–90. · DOI
- Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazár-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res. 1998;29(3):259–62.
- Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–80. · DOI
- Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16(11):876–83. · DOI · Paper page
Cited by
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Long-term side effects of glucocorticoids
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1140743 · Cited by 869
Stress and Obesity: Are There More Susceptible Individuals?
van der Valk, E. S., Savas, M., & van Rossum, E. F. C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0306-y · Cited by 402
COVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 274
Milligan Armstrong, A., Porter, T., Quek, H., White, A., Haynes, J., Jackaman, C., Villemagne, V., Munyard, K., Laws, S. M., Verdile, G., et al. (2021) · Biological Reviews · doi:10.1111/brv.12750 · Cited by 116
Metadata
- Authors
- Fardet, L., & Fève, B.
- Venue
- Drugs
- Published
- 2014-09-10
- Volume
- 74
- Issue
- 15
- Pages
- 1731-1745
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W1965283604
- Cited by
- 236
- References
- 26
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.